Core Viewpoint - The company reported a decline in revenue for Q3 2025, with a slight increase in gross margin, while net profit and net profit margin decreased year-on-year and quarter-on-quarter [2] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 646 million yuan, a year-on-year decrease of 6.40%, and a net profit of 207 million yuan, down 9.59% year-on-year [1] - In Q3 2025, the company generated revenue of 164 million yuan, a year-on-year decline of 17.01%, with a net profit of 38 million yuan, down 23.33% year-on-year [2] - The gross margin for Q3 was 53.32%, showing a year-on-year increase of 0.03 percentage points, while the net profit margin was 22.97%, down 1.89 percentage points year-on-year [2] Research and Development - The company has significantly increased its R&D investment, with R&D expenses reaching 81.62 million yuan in the first three quarters of 2025, a year-on-year increase of 27.49%, marking a historical high for the period [3] - The R&D expense ratio for the first three quarters was 12.64%, indicating a commitment to enhancing R&D capabilities and expanding the team to nearly 500 members [3] - The company is focusing on synthetic biology and peptide drugs, with plans to develop innovative drugs, including a new drug for ischemic stroke that is pending entry into phase III clinical trials [3] Future Outlook - The company is expected to see revenue growth in the coming years, with projected revenues of 832 million yuan, 978 million yuan, and 1.213 billion yuan for 2025, 2026, and 2027, respectively [4] - The net profit forecasts for the same years are 241 million yuan, 394 million yuan, and 382 million yuan, with corresponding price-to-earnings ratios of 34, 28, and 22 times [4] - The company anticipates that its collaboration with STADA on a new formulation product will begin contributing to sales in the second half of 2025 [3]

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in the company's product portfolio [1]. Group 1: Product Approval - The drug registration certificate (Certificate No. 2025S02736) for Imatinib Mesylate Tablets has been officially issued [1]. - Imatinib Mesylate Tablets are the world's first targeted molecular therapy for cancer, specifically indicated for patients with chronic myeloid leukemia (CML) in acute or accelerated phases, or those who have failed alpha-interferon treatment [1]. - The drug is also indicated for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1]. Group 2: Mechanism of Action - The active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively inhibits the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function [1]. - This mechanism results in the suppression of abnormal white blood cell proliferation [1]. - Imatinib also binds to the active site of tyrosine kinase, blocking its activity [1].

Core Viewpoint - The announcement highlights that Aoxiang Pharmaceutical's subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration certificate of Imatinib Mesylate Tablets, marking a significant milestone in cancer treatment [1]. Group 1: Company Developments - Aoxiang Pharmaceutical's subsidiary, Zhejiang Qizheng Pharmaceutical, has been granted a drug registration certificate for Imatinib Mesylate Tablets [1]. - Imatinib Mesylate is recognized as the world's first targeted molecular therapy for cancer, specifically for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) [1]. Group 2: Product Details - Imatinib Mesylate Tablets are intended for patients in the accelerated phase or blast crisis of CML, as well as those with GIST who cannot undergo surgical resection or have metastatic disease [1]. - The active ingredient, Imatinib, functions as a tyrosine kinase inhibitor, effectively suppressing the Philadelphia chromosome gene and preventing abnormal white blood cell proliferation [1].

Core Viewpoint - Aoxiang Pharmaceutical (603229) announced that its wholly-owned subsidiary, Qizheng Pharmaceutical, received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in its collaboration with STADA for the development and commercialization of this product [1] Group 1 - The drug Imatinib Mesylate Tablets is the world's first targeted molecular therapy for cancer, specifically used for treating patients with chronic myeloid leukemia (CML) in the blast phase, accelerated phase, or chronic phase after failure of alpha-interferon therapy [1] - It is also indicated for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1]

Core Viewpoint - The company, Aoxiang Pharmaceutical (603229.SH), announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in the oncology sector [1] Group 1: Product Information - Imatinib Mesylate Tablets are the world's first targeted molecular therapy for cancer, specifically indicated for patients with chronic myeloid leukemia (CML) in acute or accelerated phases, or those who have failed alpha-interferon treatment, as well as for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1] - The active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively suppresses the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function, thereby inhibiting abnormal white blood cell proliferation [1] - Imatinib also binds to the active site of tyrosine kinase, blocking its activity [1]

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in the company's product portfolio [1]. Group 1: Product Approval - The drug registration certificate (Certificate No.: 2025S02736) is for Imatinib Mesylate Tablets, which is the world's first targeted molecular therapy for cancer [1]. - Imatinib Mesylate is indicated for patients with chronic myeloid leukemia (CML) in the acute phase, accelerated phase, or chronic phase after failure of alpha-interferon treatment, as well as for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1]. Group 2: Mechanism of Action - The active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively inhibits the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function [1]. - This mechanism helps to suppress the abnormal proliferation of white blood cells and also binds to the active site of tyrosine kinase, blocking its activity [1].